Maxxam has experience providing bioanalytical support and API characterization of platinum based therapeutics such as cisplatin, carboplatin and oxaliplatin. The laboratory utilizes Inductively Coupled Mass Spectrometry (ICPMS) to provide superior sensitivity and specificity.
The laboratory has handled drug compounds containing precious metals, rare earths, bismuth, transition metals and others. Maxxam has established validated methods for metallo-drug assays using inductively coupled plasma mass spectrometry (ICP-MS) at the low to sub ng/mL levels in common matrices of clinical interest, including urine, plasma and plasma ultrafiltrate. Maxxam also has many pre-validated “off the shelf” bioanalytical methods available for other oncology drugs such as azathioprine and 6-mercaptopurine.